ProCE Banner Activity

Experts Answer Frequently Asked Questions on Myeloma Management

Clinical Thought
Experts answer frequently asked questions on key topical issues in the care of patients with myeloma, including the management of smoldering myeloma, treatment options for patients with high-risk multiple myeloma, and novel immunotherapy constructs.

Released: January 27, 2021

Expiration: January 26, 2022

Share

Faculty

Brian G. M. Durie

Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Thomas G. Martin

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Philippe Moreau

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital of Nantes
Nantes, France

Jesus San-Miguel

Jesus San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Clinica Universidad de Navarra
Universidad de Navarra
Pamplona, Spain

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Bristol Myers Squibb

GlaxoSmithKline

Karyopharm

Oncopeptides

Partners

International Myeloma Foundation

ProCE Banner

Faculty Disclosure

Primary Author

Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Brian G.M. Durie, MD, has disclosed that he has received consulting fees from Amgen, Celgene/Bristol-Myers Squibb, Janssen, and Takeda and fees from non-CME/CE services from Amgen.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, MedImmune, Oncopeptides, Takeda, and TeneoBio and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Oncopeptides, and Takeda.

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Thomas G. Martin, MD, has disclosed that he has received consulting fees from GlaxoSmithKline and funds for research support from Amgen, Janssen, and Sanofi.

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital of Nantes
Nantes, France

Philippe Moreau, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, Janssen, and Sanofi.

Jesus San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Clinica Universidad de Navarra
Universidad de Navarra
Pamplona, Spain

Jesús F. San-Miguel, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Roche, Sanofi, and Takeda.